This could finally be the solution to male pattern baldness - FDA approved Ruxolitinib and Tofacitinib

10/26/2015 - 06:17


Inhibiting a family of enzymes inside hair follicles that are suspended in a resting state restores hair growth, a new study from researchers at Columbia University Medical Center has found. The research was published today in the online edition of Science Advances.

In experiments with mouse and human hair follicles, Angela M. Christiano, PhD, and colleagues found that drugs that inhibit the Janus kinase (JAK) family of enzymes promote rapid and robust hair growth when applied to the skin.

The study raises the possibility that JAK inhibitors could be used to restore hair growth in forms of hair loss induced by male pattern baldness, and other types of hair loss that occur when hair follicles are trapped in a resting state.

READ MORE ON COLUMBIA UNIVERSITY MEDICAL CENTER

Ref: Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. *Science Advances (October 2015) | DOI: 10.1126/sciadv.1500973

LEARN MORE ABOUT RUXOLITINIB AND TOFACITINIB